CoChat

Elobixibat for the treatment of constipation

Open access
Chedid, Victor, Vijayvargiya, Priya, Camilleri, Michael · 2018 · Expert Review of Gastroenterology & Hepatology
Cited by 48

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Chronic idiopathic constipation (CC) is highly prevalent worldwide. A subset of patients with CC have reduced fecal (and by inference, intra-colonic) bile acids (BA). Elobixibat, a locally-acting ileal bile acid transporter (IBAT) inhibitor, leads to increased BA delivery to the colon and represents a new class of treatment for CC. BAs accelerate colonic transit and increase colonic secretion. Therefore, IBAT inhibitors have potential to treat patients with CC. Areas covered: Rationale for IBAT inhibitor in therapeutics, and preclinical and clinical pharmacology of elobixibat: In vitro, elobixibat is a highly potent, selective IBAT inhibitor. In humans, elobixibat accelerated colonic transit. In phase 2A, 2B and 3 studies in CC, elobixibat was efficacious, well tolerated and safe. An open-label, phase 3 trial (52 weeks) confirmed the safety of elobixibat. Elobixibat reduces LDL cholesterol, increases serum GLP-1, and has potential in metabolic syndrome. Expert commentary: Uniquely among current treatments of CC, elobixibat stimulates both motor and secretory functions in the colon. These dual effects suggest that, when approved, elobixibat may be a first-line choice for constipation associated with colonic BA deficiency and a second-line treatment for all patients with CC and constipation-predominant irritable bowel syndrome. Further studies are required to confirm efficacy for relief of CC. Once approved, elobixibat will likely become a second-line choice for treatment of CC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17474124.2018.1522248

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

  • Intestinal absorption of bile acids in health and disease

    Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215

    “…lowering plasma LDL cholesterol (see above), these small molecule inhibitors have shown promise in preclinical and clinical studies for the treatment of chronic constipation (65, 78, 276, 348), NASH (289, 310), type 2 diabetes mellitus (71, 249, 379, 426), and cholestatic pruritus (24, 153, 264).”
  • The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus

    De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025) · Nutrients · doi:10.3390/nu17193038 · Cited by 4

    “These findings corroborate initial studies that demonstrated the benefits of elobixibat on lipid and glucose metabolism, particularly through the elevation of GLP-1 plasma levels [114,115].”

See all 48

Metadata

Authors
Chedid, V., Vijayvargiya, P., & Camilleri, M.
Venue
Expert Review of Gastroenterology & Hepatology
Published
2018-09-20
Volume
12
Issue
10
Pages
951-960
ISSN
  • 1747-4124 (ISSN-L)
  • 1747-4132
OpenAlex
W2891577238
Cited by
48
References
18
FWCI
3.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elobixibat for the treatment of constipation. https://app.cochat.ai/papers/10.1080/17474124.2018.1522248
The paper
Chedid, V., Vijayvargiya, P., & Camilleri, M. (2018). Elobixibat for the treatment of constipation. Expert Review of Gastroenterology & Hepatology. https://doi.org/10.1080/17474124.2018.1522248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.